The invention relates to a stable liposomal dry powder inhaler (LDPI) formulation of Azithromycin for pulmonary delivery which provides prolonged and site specific release. The present invention also relates to the LDPI formulation of Azithromycin which make it possible to reduce the dose of Azithromycin, exposure to systemic circulation and site specific side effects.